



1 ECT response after relapse during continuation repetitive transcranial
2 magnetic stimulation. A case report

3 A. Conca^{a,*}, W. Hrubos^a, J. Di Pauli^a, P. König^a, A. Hausmann^b

4 ^a Department of Psychiatry I, Regional Hospital of Rankweil, LKH Rankweil, Valunastr. 16, Rankweil 6830, Austria

5 ^b Department of General Psychiatry, University Hospital Innsbruck, Austria

6 Received 10 January 2003; received in revised form 1 July 2003; accepted 21 July 2003

7
8 **1. Introduction**

9 rTMS is a new tool in the treatment of depression. Most
10 scientific papers report on significant short-term antidepressant
11 effects in the treatment of patients suffering from non-
12 psychotic major depressive disorder (MDD) [5]. Need for
13 continuation treatment seems to be indicated as latency to
14 relapse without therapy was reported to be rather short [2].
15 Till date only one paper [10] deals with rTMS as a continua-
16 tion or maintenance therapy. Recent work shows that the
17 3 and 6 months outcome of rTMS treated patients equals the
18 outcome of ECT in non-psychotic MDD [3] and that patients
19 could benefit of a rTMS substitution for ECT in a course of
20 ECT [9]. We describe a case in which we administered rTMS
21 as a continuation treatment after a response to the acute
22 rTMS course. The chosen rTMS frequency during continua-
23 tion treatment was based on the APA-ECT guidelines for
24 continuation treatment [1] and the stimulus intensity on the
25 results published by Pridmore indicating that rTMS corre-
26 sponds to ECT in the relation of 2:1 [9].

27 **2. Case report**

28 Ms. F is a 48-year-old, right handed, whose major depres-
29 sion, according to ICD-10 criteria, was diagnosed for the first
30 time in 1994. Additionally she is affected by a known chronic
31 hepatic disorder. In 1996 she was treated the first time at our
32 hospital after a failed suicide attempt. Because of the treat-
33 ment resistance to various antidepressants we started a
34 course of ECT. She gained benefit from the ECT in the acute
35 phase as well as in the maintenance period for 3 years.
36 However she wanted to discontinue the maintenance ECT. A

half year later she visited our ambulatory center during a mild
depressive episode lasting an average of 4 weeks. The current
medication then was vitamin E, gestagenes and St. John's
wort 900 mg/day. After detailed information about the risks
and side effects of the rTMS as an alternative treatment to
ECT she gave her written informed consent. The laboratory
examination showed raised liver enzymes, the other routine
parameters were within the limits. The EEG showed tempo-
ral theta activities, especially under provocation, but without
any signs of epileptic activities. The CCT was normal.

37
38
39
40
41
42
43
44
45
46
47 **3. Methods**

48 *3.1. rTMS protocol*

49 We used the Figure 8 coil to deliver rTMS with a Cadwell
50 stimulator. According to Klein et al. [7] we applied rTMS to
51 the right dorsolateral prefrontal cortex (DLPC) at a stimulus
52 intensity of 110% of the motor threshold of abductor digiti
53 minimi muscle, 1 Hz, 600 s and 1 train for the total dose of
54 600 stimuli each session for a total of 3000 stimuli. Acute
55 treatment consisted of five sessions during the first week.
56 After the first week we switched to the continuation phase
57 with a frequency of three times a week for 3 weeks for a total
58 of 5400 stimuli followed by a once weekly stimulation for
59 further 3 weeks for a total of 1800 stimuli, before starting
60 rTMS biweekly. A total of 10,800 stimuli were administered.

61 *3.2. ECT protocol*

62 We administered the electrical stimuli with a MECT-SR
63 1 device using the seizure threshold procedure for unilateral
64 ECT the d'Elia non-dominant electrode placement was
65 implemented. Electrode placement was decided on the basis
66 of standard clinical criteria [1]. After switching from rTMS
67 we started the acute phase ECT treatment with three sessions
68 weekly up to a total of 15.

* Corresponding author. Fax: +43-5522-403-6516.
E-mail address: andreas.conca@lkh.at (A. Conca).

69 4. Results

70 When we started the course of rTMS, the patient scored
71 18 in the 24-item HAMD score and 5 in the CGI score. She
72 was treated on an outpatient basis and had a response rate of
73 more than 50% in both scales under the acute phase TMS and
74 St. John's wort. Upon her wish and after receiving her written
75 informed consent we started the continuation rTMS. The
76 patient remained stable for another 8 weeks. No side effects
77 were observed during the therapy.

78 After switching from weekly treatment to biweekly (one
79 session) the patient relapsed suddenly 2 days after the last
80 rTMS without any predictors. She was rehospitalized expe-
81 riencing a recurrent depressive severe episodes without psy-
82 chotic symptoms (according to ICD-10; F32.2). The HAMD
83 score was 23 and the CGI score was 6. She was switched to
84 ECT after her given written informed consent. Her response
85 rate was more than 60% within 4 weeks in both, the CGI and
86 the HAMD score. Based on the previous experiences with
87 regard to her past compliance she got continuation ECT as an
88 outpatient after her remission.

89 5. Discussion

90 ECT is known as a powerful treatment in patients suffer-
91 ing from therapy resistant depression. One of the adverse
92 events may be partial amnesia especially in impersonal
93 memory [8]. Some authors argue that rTMS is an alternative
94 method to treat patients suffering from non-psychotic MDD
95 which can achieve results approaching these of ECT as the
96 antidepressive short-term outcome of both therapies is con-
97 sidered to be similar [6]. The positive effects we found in
98 terms of augmentation properties after acute rTMS treatment
99 go along with findings of other studies [4]. After an impres-
100 sive response (HAMD <9) during the acute phase of five
101 rTMS sessions we switched the patient to the continuation
102 phase. Missing information about the relation of stimulation
103 frequency between rTMS and ECT we decided to use the
104 equation of Pridmore et al. [9] despite knowing that Pridmore
105 used a high frequency stimulation. Upon her request the
106 patient was scheduled to three sessions weekly for 1 week,
107 subsequently once per week for 6 weeks, which is a low
108 session incidence. In fact the small amount of sessions per
109 week might have contributed to the relapse the patient suf-
110 fered. An increased severity of symptoms during relapse is

expected during a failure of continuation treatment. Never-
111 theless, the sudden relapse without any predictors 2 days
112 after the first biweekly adopted rTMS is noteworthy. How-
113 ever, switching the patient from rTMS to ECT led to a
114 remission; this observation stays in accordance to Dannon
115 and Grunhaus [3] who reported that switching rTMS non-
116 responders to ECT was successful for 40% of their sample. In
117 this case rTMS had a good clinical impact as an acute treat-
118 ment strategy but failed to reveal effectiveness in mainte-
119 nance therapy. The decrease in number of rTMS sessions per
120 week and thus, a decrease in stimulation intensity could be
121 responsible suggesting a weaker potency of rTMS than ECT
122 in the continuation treatment. 123

References 124

- [1] American Psychiatric Association. The practice of ECT: recommen-
125 dations for treatment, training and privileging. Washington (DC):
126 American Psychiatric Press; 2001 Task force report on ECT. 127
- [2] Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE,
128 Hu XS, et al. A randomized clinical trial of repetitive transcranial
129 magnetic stimulation in the treatment of major depression. *Biol Psy-*
130 *chiatry* 2000;15:332-7. 131
- [3] Dannon PN, Grunhaus L. Effect of electroconvulsive therapy in
132 repetitive transcranial magnetic stimulation non-responder MDD
133 patients: a preliminary study. *Int J Neuropsychopharmacol* 2001;4(3):
134 265-8. 135
- [4] Eschweiler GW, Plewnia C, Bartels M. Welche depressiven Patienten
136 profitieren von präfrontaler repetitiver transkranieller Magnetstimula-
137 tion (rTMS)? *Fortschr Neurol Psychiatr* 2001;69:402-9. 138
- [5] George M, Lisanby S, Sackeim H. Transcranial magnetic stimulation.
139 Applications in neuropsychiatry. *Arch Gen Psychiatry* 1999;56:300-
140 11. 141
- [6] Janicak PG, Dowd SM, Martis B, Alam D, Beedle D, Krasuski J, et al.
142 Repetitive transcranial magnetic stimulation versus electroconvulsive
143 therapy for major depression: preliminary results of a randomized
144 trial. *Biol Psychiatry* 2002;15(8):659-67. 145
- [7] Klein E, Kreinin I, Chistyakov A, Koren D, Mecz L, Marmur S, et al.
146 Therapeutic efficacy of right prefrontal slow repetitive transcranial
147 magnetic stimulation in major depression: a double-blind controlled
148 study. *Arch Gen Psychiatry* 1999;56:315-20. 149
- [8] Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA. The
150 effects of electroconvulsive therapy on memory of autobiographical
151 and public events. *Arch Gen Psychiatry* 2000;57(6):591-2. 152
- [9] Pridmore S, Bruno R, Turnier-Shea Y, Reid P, Rybak M. Comparison
153 of unlimited numbers of rTMS and ECT treatment sessions in major
154 depressive episode. *Int J Neuropsychopharmacol* 2000;3:129-34. 155
- [10] Smesny S, Volz HP, Liepert J, Tauber R, Hochstetter A, Sauer H.
156 Repetitive transcranial magnetic stimulation (rTMS) in the acute and
157 long-term therapy of refractory depression—a case report. *Nervenarzt*
158 2001;72(9):734-8. 159